Preclinical evaluation of89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies

mAbs

Volumn 6, Issue 2, 2014, Pages 567-575

  Vugts, Danielle J ^a   Heuveling, Derrek A ^a   Stigter van Walsum, Marijke ^a   Weigand, Stefan ^b   Bergstrom, Mats ^c   Van Dongen, Guus A M S ^a   Nayak, Tapan K ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Discovery Oncology   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

89Zr immuno PET; CD44; RG7356

Indexed keywords

HERMES ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RG7356; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; ZIRCONIUM 89 RG7356; RADIOISOTOPE; RG7356;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CONTROLLED STUDY; MACACA FASCICULARIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SALIVARY GLAND; SINGLE DRUG DOSE; SPLEEN; TUMOR XENOGRAFT; 89ZR-IMMUNO-PET; ANIMAL; CARCINOMA; CD44; CHEMISTRY; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); TISSUE DISTRIBUTION; TUMOR CELL LINE;

89ZR-IMMUNO-PET; CD44; RG7356;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD44; CARCINOMA; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; MACACA FASCICULARIS; MICE; RADIOISOTOPES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIRCONIUM;

EID: 84896533782     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27415     Document Type: Article

References (30)

1. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71:241-319; PMID:9111868; http://dx.doi.org/10.1016/S0065-230X(08)60101-3
2. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4:33-45; PMID:12511867; http://dx.doi.org/10.1038/nrm1004
3. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004; 35:211-31; PMID:15339042; http://dx.doi.org/10.1023/B:HIJO.0000032354.94213.69
4. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008; 18:260-7; PMID:18467123; http://dx.doi.org/10.1016/j.semcancer.2008.03.015
5. Weigand S, Herting F, Maisel D, Nopora A, Voss E, Schaab C, Klammer M, Tebbe A. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist. Cancer Res 2012; 72:4329-39; PMID:22777824; http://dx.doi.org/10.1158/0008-5472.CAN-12-0136
6. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12:6064-72; PMID:17062682; http://dx.doi.org/10.1158/1078-0432.CCR-06-0910
7. Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, Heider KH, Stehle G, Snow GB, van Dongen GA. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003; 52:576-82; PMID:14627130; http://dx.doi.org/10. 1007/s00262-003-0396-5
8. Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9:3961S-72S; PMID:14506195
9. Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, Qi J, Robert-Lezenes J, Chomienne C, Smadja-Joffe F. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004; 45:1501-10; PMID:15370200; http://dx.doi.org/10.1080/1042819042000206687
10. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A 2013; 110:6127-32; PMID:23530247; http://dx.doi.org/10.1073/pnas.1221841110
11. Nácher M, Blázquez AB, Shao B, Matesanz A, Prophete C, Berin MC, Frenette PS, Hidalgo A. Physiological contribution of CD44 as a ligand for E-Selectin during inflammatory T-cell recruitment. Am J Pathol 2011; 178:2437-46; PMID:21457936; http://dx.doi.org/10.1016/j.ajpath.2011.01.039
12. Johnson P, Ruffell B. CD44 and its role in inflammation and inflammatory diseases. Inflamm Allergy Drug Targets 2009; 8:208-20; PMID:19601881; http://dx.doi.org/10.2174/187152809788680994
13. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124:71-82; PMID:7507492; http://dx.doi.org/10.1083/jcb.124.1.71
14. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56:1057-62; PMID:2466575; http://dx.doi.org/10.1016/0092- 8674(89)90638-7
15. Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989; 56:1063-72; PMID:2466576; http://dx.doi. org/10.1016/0092-8674(89)90639-9
16. Nottenburg C, Rees G, St John T. Isolation of mouse CD44 cDNA: structural features are distinct from the primate cDNA. Proc Natl Acad Sci U S A 1989; 86:8521-5; PMID:2682651; http://dx.doi.org/10.1073/pnas.86.21.8521
17. van Gog FB, Brakenhoff RH, Snow GB, van Dongen GA. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice. Cancer Immunol Immunother 1997; 44:103-11; PMID:9177472; http://dx.doi.org/10.1007/ s002620050362
18. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 2010; 25:375-85; PMID:20707716; http://dx.doi.org/10.1089/cbr.2010.0812
19. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; 83:97-104; PMID:1988695; http://dx.doi.org/10.1093/jnci/83.2.97
20. Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, et al. Performance of immuno-positron emission tomography with zir-conium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006; 12:2133-40; PMID:16609026; http://dx.doi.org/10.1158/1078-0432.CCR-05-2137
21. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87:586-92; PMID:20357763; http://dx.doi.org/10.1038/clpt.2010.12
22. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003; 9:1639-47; PMID:12738716
23. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 2009; 15:6709-15; PMID:19825951; http://dx.doi.org/10.1158/1078-0432.CCR-09-0536
24. Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 2009; 218:380-90; PMID:19334050; http://dx.doi.org/10.1002/path.2545
25. Vugts DJ, Visser GW, van Dongen GA. 89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals. Curr Top Med Chem 2013; 13:446-57; PMID:23432007; http://dx.doi.org/10.2174/1568026611313040005
26. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003; 44:1271-81; PMID:12902418
27. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem 2009; 20:825-41; PMID:19125647; http://dx.doi.org/10.1021/bc800299f
28. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 2012; 53:113-20; PMID:22213822; http://dx.doi.org/10.2967/jnumed.111.094169
29. Young D, Findlay H, Hahn S, Cechetto L, McConkey F. Chimeric and humanized Anti-CD44 antibodies that mediate cancer cell cytotoxicity. WO Patent 2,008,144,890, 2008.
30. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72:77-89; PMID:6086763; http://dx.doi.org/10.1016/0022-1759(84)90435-6